At Biogen, we are committed to improving the lives of patients living with serious illnesses. Through relentless innovation and leading-edge manufacturing capabilities, we develop novel therapies to address high unmet medical needs. We have extended that mission to the pursuit of developing biosimilars of advanced biologics.

Biosimilars are a classification of biologic medicines that are similar to currently available biologic therapies known as originators. Now that some of these medicines have reached patent expiry, regulators across the world are creating pathways to allow for similar versions — biosimilars — of originator biologics to enter the market.1, 2

Biosimilar medicines can help reduce the total expected expenditure of these much-needed biologic therapies, thereby increasing access for patients.3 Biosimilars offer a way to deliver significant cost savings and expand access to biologics, while contributing to healthcare sustainability and helping to support investment in future medical innovations.

Having successfully delivered complex originator biologics for more than 30 years, Biogen is one of only a handful of companies with the manufacturing capabilities and the deep scientific expertise needed to produce biosimilars of advanced biologics. By leveraging our heritage of scientific innovation, bringing biosimilars to those who need them most is a compelling way in which we can make a difference in the lives of the patients we serve.

REFERENCES
1. European Commission, Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products, page 6
2. U.S. Food and Drug Administration, Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, page 5
3. European Commission, Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products, page 36